drugset / Trial / NCT06379685
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase I clinical study to evaluate the safety and tolerability of PRO-190 ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in ocular surface integrity, changes in the ocular comfort index (OCI) score, and IOP measurement compared to Systane Ultra®.
Timeline
- Start
- 2025-12-30
- Primary completion
- 2026-12-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Polyethylene glycol 400 | Unknown | 0.3 % | Other |
| Subject | Polyethylene glycol 400 | Unknown | 0.4 % | Other |
| Subject | Propylene Glycol | Small molecule | 0.3 % | Other |